BRPI0916574A2 - derivados de diazepano e piperazina moduladores de receptores de quiomiocinas - Google Patents

derivados de diazepano e piperazina moduladores de receptores de quiomiocinas

Info

Publication number
BRPI0916574A2
BRPI0916574A2 BRPI0916574A BRPI0916574A BRPI0916574A2 BR PI0916574 A2 BRPI0916574 A2 BR PI0916574A2 BR PI0916574 A BRPI0916574 A BR PI0916574A BR PI0916574 A BRPI0916574 A BR PI0916574A BR PI0916574 A2 BRPI0916574 A2 BR PI0916574A2
Authority
BR
Brazil
Prior art keywords
diazepane
chemokine receptor
receptor modulators
piperazine derivatives
piperazine
Prior art date
Application number
BRPI0916574A
Other languages
English (en)
Inventor
Alfred Binggeli
Fabienne Ricklin
Guido Hartmann
Hans P Maerki
Jean-Michael Adam
Johannes Aebi
Luke Green
Olivier Roche
Patrizio Mattei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0916574A2 publication Critical patent/BRPI0916574A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0916574A 2008-07-28 2009-07-20 derivados de diazepano e piperazina moduladores de receptores de quiomiocinas BRPI0916574A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161278 2008-07-28
PCT/EP2009/059270 WO2010012619A1 (en) 2008-07-28 2009-07-20 Diazepan and piperazine derivatives modulators of chemokine receptors

Publications (1)

Publication Number Publication Date
BRPI0916574A2 true BRPI0916574A2 (pt) 2015-11-10

Family

ID=41130181

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916574A BRPI0916574A2 (pt) 2008-07-28 2009-07-20 derivados de diazepano e piperazina moduladores de receptores de quiomiocinas

Country Status (13)

Country Link
US (1) US8138175B2 (pt)
EP (1) EP2321285A1 (pt)
JP (1) JP5389917B2 (pt)
KR (1) KR101354421B1 (pt)
CN (1) CN102112451B (pt)
AR (1) AR072754A1 (pt)
AU (1) AU2009276090A1 (pt)
BR (1) BRPI0916574A2 (pt)
CA (1) CA2730770A1 (pt)
IL (1) IL209591A0 (pt)
MX (1) MX2011000755A (pt)
TW (1) TW201008921A (pt)
WO (1) WO2010012619A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
EP2484674A1 (en) * 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
CN103613530B (zh) * 2013-12-02 2015-08-19 江苏弘和药物研发有限公司 一种芴甲氧羰基-3-哌啶醇的合成方法
CN111423454B (zh) * 2020-04-24 2021-06-22 苏州大学 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用
WO2022057849A1 (zh) * 2020-09-17 2022-03-24 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
CN112920079A (zh) * 2021-01-29 2021-06-08 广西田园生化股份有限公司 一种酰胺化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
CN1187342C (zh) * 2000-05-25 2005-02-02 弗·哈夫曼-拉罗切有限公司 取代的1-氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
DE60114413T2 (de) * 2000-05-25 2006-07-27 F. Hoffmann-La Roche Ag Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
AU2002326948A1 (en) * 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
EP1619193A4 (en) * 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
US20070238723A1 (en) * 2004-10-15 2007-10-11 Goble Stephen D Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
JP2006137718A (ja) * 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
JP2008528604A (ja) * 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
KR101176697B1 (ko) * 2006-04-20 2012-08-23 에프. 호프만-라 로슈 아게 케모카인 수용체의 다이아제판 유도체 조절자
MX2009005252A (es) * 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.

Also Published As

Publication number Publication date
AR072754A1 (es) 2010-09-15
CA2730770A1 (en) 2010-02-04
WO2010012619A1 (en) 2010-02-04
TW201008921A (en) 2010-03-01
CN102112451B (zh) 2014-01-22
JP5389917B2 (ja) 2014-01-15
JP2011529095A (ja) 2011-12-01
KR20110025228A (ko) 2011-03-09
AU2009276090A1 (en) 2010-02-04
IL209591A0 (en) 2011-01-31
KR101354421B1 (ko) 2014-01-22
EP2321285A1 (en) 2011-05-18
US20100022518A1 (en) 2010-01-28
CN102112451A (zh) 2011-06-29
MX2011000755A (es) 2011-02-24
US8138175B2 (en) 2012-03-20

Similar Documents

Publication Publication Date Title
BRPI0918949A2 (pt) moduladores de receptores de 5-ht2a e piperazina d3
DK2262808T3 (da) Chemokinreceptormodulatorer
BRPI0817644A2 (pt) Derivados de piperidina e piperazina
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
BRPI1004349A2 (pt) conjunto de rótulo e uso do mesmo
BRPI0921551A2 (pt) distribuidor e unidade de recarga
PT2496567T (pt) Novos moduladores de quinase benzopiran
DK2245130T3 (da) Ts23 -alpha-amylasevarianter med ændrede egenskaber
BRPI0914544A2 (pt) derivados de pirimidona substituídos
BRPI0920521A2 (pt) combinação farmacêutica
ES2465673T9 (es) Derivados de pirimidina
ES2385606T8 (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0815092A2 (pt) Moduladores duais de receptores 5-ht2a e d3
HRP20170959T1 (hr) Farmaceutska suspenzija
EP2116533A4 (en) Glucokinase AKTIVATOR
BRPI0822058A2 (pt) Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
BRPI0908815A2 (pt) inibidores do receptor de quimiocina cxcr3
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0916679A2 (pt) 5-alquinil-pirimidinas
EP2473048A4 (en) POSITIVE PYRANYL-ARYL-METHYL-BENZOCHINAZOLINONE ALLOSTERIC M1 RECEPTOR MODULATORS
BRPI0816922A2 (pt) Moduladores tieno e furo-pirimidina do receptor de histamina h4
ECSP10010558A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
BRPI0820779A2 (pt) Derivados de 4-amino-pirimidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.